| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5378703 (Pediatric) | SANDOZ | Sulfonamides useful as carbonic anhydrase inhibitors |
Oct, 2012
(11 years ago) | |
| US5461081 | SANDOZ | Topical ophthalmic pharmaceutical vehicles |
Oct, 2012
(11 years ago) | |
|
US5461081 (Pediatric) | SANDOZ | Topical ophthalmic pharmaceutical vehicles |
Apr, 2013
(11 years ago) | |
Azopt is owned by Sandoz.
Azopt contains Brinzolamide.
Azopt has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Azopt are:
- US5378703*PED
- US5461081
- US5461081*PED
Azopt was authorised for market use on 01 April, 1998.
Azopt is available in suspension/drops;ophthalmic dosage forms.
Azopt can be used as method for delivery.
The generics of Azopt are possible to be released after 24 April, 2013.
Drugs and Companies using BRINZOLAMIDE ingredient
Market Authorisation Date: 01 April, 1998
Treatment: Method for delivery
Dosage: SUSPENSION/DROPS;OPHTHALMIC
More Information on Dosage
AZOPT family patents
